Viatris announced it has launched Hulio® (biosimilar adalimumab) in Canada. Hulio® is available in a 50mg/ml...
Viatris launches Hulio® (biosimilar adalimumab) in Canada
read more
Fresenius Kabi launches Idacio® (biosimilar adalimumab) in Canada
Fresenius Kabi announced it has launched Idacio® (biosimilar adalimumab) in Canada. Idacio® is available in 50mg/ml...
Sandoz launches Hyrimoz® (biosimilar adalimumab) in Canada
Sandoz announced that it has launched Hyrimoz®, its 50mg/mL biosimilar adalimumab in Canada. Hyrimoz® was approved by...
FDA accepts Coherus’ BLA for biosimilar adalimumab
Coherus Biosciences announced the FDA has accepted the BLA for its biosimilar adalimumab candidate (CHS-1420). Coherus...
Fujifilm and Mylan launch Hulio® (biosimilar adalimumab) in Japan
Fujifilm Kyowa Kirin Biologics and Mylan announced the launch of Hulio® in Japan. Hulio® is available in a 40mg/0.8mL...
Celltrion’s Yuflyma® (biosimilar adalimumab) approved in the EU
Celltrion announced it received EC marketing authorisation for Yuflyma® (biosimilar adalimumab) across all...
Tabuk partners with Prestige on Tuznue®(biosimilar trastuzumab)
Saudi Arabia's Tabuk Pharmaceuticals announced it has reached an exclusive licensing and distribution agreement with...
EU approves Biocon’s Kixelle®(biosimilar insulin aspart)
Biocon and Viatris announces Kixelle® (biosimilar insulin aspart) has received marking authorisation approval in the...
Roche releases Ph III results of follow-on faricimab
Roche announced new Ph III data shows faricimab (given at intervals of up to four months) is non-inferior compared to...
Lannett and HEC reach insulin aspart agreement
Lannett announces it has entered into an agreement with the HEC Group of companies for biosimilar insulin aspart....
Celltrion commences Ph III aflibercept trials
Celltrion announces it has commenced Ph III trials of its proposed aflibercept biosimilar.
Roche reports huge erosion of YoY CER growth in key areas
Roche reports a huge erosion of its year on year CER growth in key areas, attributing this decline to COVID-19 impacts...
Celltrion discusses its adalimumab biosimilar
In an interview with the Centre for Biosimilars the head of Celltrion's Medical and Marketing Division, HoUng Kim PhD,...
Enzene Biosciences receives biosimilar teriparatide approval
Enzene Biosciences announces it has received marketing authorisation for its biosimilar teriparatide in India.
Coherus Biosciences and Junshi Biosciences reach toripalimab agreement
Coherus Biosciences announces it has reached an agreement with Junshi Biosciences for the development and...
Celltrion receives approval for biosimilar infliximab from Health Canada
Celltrion announces it has received a notice of compliance from Health Canada for Remsima® SC (subcutaneous...